Zacks - BIOPHARMX (BPMX) BPMX: Phase IV of VI2LET initiated, data expected by the end of 2016; Phase IIa of BPX01 for acne completed enrollment, data expected in mid-2016.

Report

Zacks

BPMX: Phase IV of VI2LET initiated, data expected by the end of 2016; Phase IIa of BPX01 for acne completed enrollment, data expected in mid-2016.

27/04/2016 11 EN

Underlying

BIOPHARMX

See profile

US09072X1019 United States

Provider

Zacks

Zacks Investment Research is a Chicago based firm with over 30 years of experience in providing institutional and individual investors with the analytical tools and financial information necessary to the success of their investment process.

See profile

Other Reports on these Companies

Zacks

BPMX: Positive feedback from the FDA received with respect to the Phase III design

December 15, 2017 December 15, 2017 15 EN

Zacks

BPMX: Positive data from Phase IIb of BPX01 for acne announced,

June 15, 2017 June 15, 2017 15 EN

Zacks

BPMX: Positive top line data from Phase IIb of BPX01 for acne announced

May 22, 2017 May 22, 2017 13 EN

PBSV: Steady as she goes

July 24, 2020 July 24, 2020 5 EN

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

July 9, 2020 July 9, 2020 7 EN

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

July 2, 2020 July 2, 2020 7 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BPMX: Phase IV of VI2LET initiated, data expected by the end of 2016; Phase IIa of BPX01 for acne completed enrollment, data expected in mid-2016.

BPMX: Positive feedback from the FDA received with respect to the Phase III design

BPMX: Positive data from Phase IIb of BPX01 for acne announced,

BPMX: Positive top line data from Phase IIb of BPX01 for acne announced

PBSV: Steady as she goes

BCLI: KOL Event Gives Overview of the use of NurOwnÂ® in Alzheimerâ€™s Disease; Raising Valuation to $25/Share...

MNOV: FDA Gives OK to Initiate Clinical Trial of MN-166 to Prevent ARDS in COVID- 19 Patients...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe